Clinical trials, such as the NSABP B-31 trial and N9831 trial, have suggested potential benefits from adjuvant trastuzumab treatment for these patients with early-stage HER2-low expression breast cancer [6]. The gene discussed is ERBB2; the disease is breast cancer.